Structured exercise program,
does it really help with Reduced recurrence, new primary cancer, or death after adjuvant chemotherapy for resected colon cancer?
research showsA three-year structured exercise program after adjuvant chemotherapy for resected colon cancer is rated A with 82 points. CHALLENGE (Courneya 2025, NEJM) randomized 889 participants and followed them for a median 7.9 years. The prespecified disease-free-survival primary endpoint succeeded, HR 0.72 (95% CI 0.55 to 0.94), and overall survival also improved, HR 0.63 (0.43 to 0.94). This large publicly funded hard-outcome randomized trial has no reason to remain at B. It is not at the top of A because the exercise intervention was unblinded and the intensive three-year supervision and behavioral support limit transferability to routine care. Verdict 1723, which is B with 72 points, and verdict 1557, which is C with 55 points, concern different purposes and indications, and their evidence was not mixed.
ads claimMarketing may reduce the intervention to generic advice to exercise, but the trial used a three-year program with individualized goals, exercise-specialist contact, and long-term behavioral support.
Useful facts when choosing a product
- The intervention included exercise-specialist supervision and behavioral support rather than written self-exercise advice alone.
- It began after completion of adjuvant chemotherapy and does not replace surgery or chemotherapy.
- Clinical assessment and gradual prescription should account for cardiopulmonary and musculoskeletal status and treatment sequelae.
What the research actually shows
CHALLENGE randomized 889 patients with high-risk stage II or stage III resected colon cancer who had completed adjuvant chemotherapy at 55 centers: 445 to structured exercise and 444 to health-education materials. The actual primary analysis included all 889 by intention to treat. After a three-year intervention and median 7.9-year follow-up, the disease-free-survival primary endpoint succeeded; five-year disease-free survival was 80.3% versus 73.9%. A 2022 meta-analysis of 13 observational studies and 19,135 patients found overall- and cancer-specific-survival associations but not disease-free survival, so it does not replace the randomized evidence.
Why this is classified as A (82)
In the 889-participant publicly funded CHALLENGE hard-outcome trial, disease-free survival improved with HR 0.72 and overall survival with HR 0.63, supporting A with 82 points. The unblinded intervention and intensive three-year supervision and behavioral support keep it below the top of A.
Counterpoint. Structured support can reduce recurrence, new cancer, or death in eligible colon-cancer survivors, but the unblinded intervention and intensive three-year supervision and behavioral support are difficult to transfer directly to routine care.
Rejudgment record. Cross-check applied — Applied A for direct hard-outcome success after median 7.9-year follow-up in the 889-participant publicly funded CHALLENGE trial, while accounting for the unblinded intervention and limited routine-care transferability of three years of supervision and behavioral support
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved disease-free survival | A | The prespecified primary endpoint succeeded in 889 intention-to-treat participants, HR 0.72 (95% CI 0.55 to 0.94). |
| Improved overall survival | A | Overall survival also improved, HR 0.63 (95% CI 0.43 to 0.94). |
| Improved physical functioning | B | SF-36 physical functioning improved substantially at six months and was maintained through 24 months. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Courneya KS et al. CHALLENGE 2025 | Phase 3 multicenter randomized controlled trial | 1 | Public and charitable funding including the Canadian Cancer Society, Canadian Institutes of Health Research, Australian NHMRC, and Cancer Research UK | Disease-free survival composite of recurrence, new primary cancer, or death | The disease-free-survival primary endpoint succeeded, HR 0.72 (95% CI 0.55 to 0.94), P=0.02; overall survival also improved, HR 0.63 (0.43 to 0.94). | Key direct hard-outcome evidence |
| Choy KT et al. 2022 | Systematic review and meta-analysis | 19,135 | No study funding reported; authors declared no competing interests | Overall, cancer-specific, and disease-free survival | Activity was associated with overall and cancer-specific survival, but not significantly with disease-free survival, and observational confounding remained. | Indirect supportive pre-randomized evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Structured exercise program x Reduced recurrence, new primary cancer, or death after adjuvant chemotherapy for resected colon cancer — Evidence Grade A·82. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/structured-exercise-after-adjuvant-chemotherapy-colon-cancer-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.